Literature DB >> 19419357

Prescription pattern of codeine for non-malignant pain: a pharmacoepidemiological study from the Norwegian Prescription Database.

O M S Fredheim1, S Skurtveit, A Moroz, H Breivik, P C Borchgrevink.   

Abstract

BACKGROUND: Opioid prescription for pain relief is increasing. Codeine is the dominating opioid in several European countries, with Norway being among the highest codeine users. AIM: To determine whether codeine is primarily used for acute pain or whether there is a prescription pattern indicating problematic opioid use.
METHODS: All pharmacies in Norway are obliged to submit data electronically to the Norwegian Prescription Database at the Norwegian Institute of Public Health on all dispensed prescriptions. Because all prescriptions are identified with a unique person identifier, it is possible to identify all prescriptions to one subject. All subjects who had prescription(s) of codeine dispensed to them in 2004, 2005 or 2006 are included in the study.
RESULTS: 385 190 Norwegian persons had at least one prescription of codeine dispensed to them due to non-cancer pain in 2005, corresponding to a 1-year periodic prevalence of 8.3%. 223 778 (58%) received only one prescription in 2005, 121 025 (31%) received more than one prescription but <120 defined daily doses (DDDs), 30 939 (8%) received between 120 and 365 DDDs, 7661 (2%) between 365 and 730 DDDs, while only 1787 (0.5%) exceeded the maximum recommended dose of 730 DDDs. In the latter group, co-medication with benzodiazepines (65%) and carisoprodol (45%) was prevalent.
CONCLUSION: About one in 10 adult persons in Norway were dispensed codeine in 2005. A majority (58%) received codeine only once, most likely for acute pain, whereas a small minority (0.5%) had a prescription pattern indicating problematic opioid use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419357     DOI: 10.1111/j.1399-6576.2009.01910.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

Review 1.  Harmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000-2013).

Authors:  Bianca Blanch; Nicholas A Buckley; Leigh Mellish; Andrew H Dawson; Paul S Haber; Sallie-Anne Pearson
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

2.  Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study.

Authors:  Marte Handal; Anders Engeland; Marit Rønning; Svetlana Skurtveit; Kari Furu
Journal:  Eur J Clin Pharmacol       Date:  2011-04-12       Impact factor: 2.953

3.  Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data.

Authors:  Ingrid Schubert; Peter Ihle; Rainer Sabatowski
Journal:  Dtsch Arztebl Int       Date:  2013-01-25       Impact factor: 5.594

4.  Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse.

Authors:  Maria Lurenda Westergaard; Ebba Holme Hansen; Charlotte Glümer; Rigmor Højland Jensen
Journal:  Eur J Clin Pharmacol       Date:  2015-05-14       Impact factor: 2.953

5.  Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation.

Authors:  J L Johnson; P E Rolan; M E Johnson; L Bobrovskaya; D B Williams; K Johnson; J Tuke; M R Hutchinson
Journal:  Transl Psychiatry       Date:  2014-11-11       Impact factor: 6.222

6.  A qualitative evidence synthesis to explore healthcare professionals' experience of prescribing opioids to adults with chronic non-malignant pain.

Authors:  Fran Toye; Kate Seers; Stephanie Tierney; Karen Louise Barker
Journal:  BMC Fam Pract       Date:  2017-11-25       Impact factor: 2.497

7.  Understanding long-term opioid prescribing for non-cancer pain in primary care: a qualitative study.

Authors:  Carolyn McCrorie; S José Closs; Allan House; Duncan Petty; Lucy Ziegler; Liz Glidewell; Robert West; Robbie Foy
Journal:  BMC Fam Pract       Date:  2015-09-11       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.